GlobeNewsWire
30 Mar 2026, 11:15 UTC · 29w ago
Verdict
Headline takes no side. We score RPRX +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 80% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Royalty Pharma and Johnson & Johnson entered a co-funding agreement totaling $500 million across 2026 and 2027 to develop the autoimmune drug JNJ-4804.
More positive than 81% of claims this week
JNJ-4804 is a novel co-antibody therapy targeting both IL-23 and TNF pathways for chronic immune-mediated diseases.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 57% of claims this week
Which stocks this story touches
More positive than 80% of ticker scores this week
The company announced a $500 million R&D co-funding agreement to advance a promising new therapy for autoimmune diseases.
More positive than 69% of ticker scores this week
Collaborating with Royalty Pharma to advance the development of its novel co-antibody therapy JNJ-4804.
More positive than 74% of relationship scores this week
[mutual] Royalty Pharma entered a $500 million R&D co-funding agreement with Johnson & Johnson to develop JNJ-4804.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on GSK's Trelegy.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Pfizer's Nurtec ODT and the Astellas/Pfizer product Xtandi.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Xtandi, developed by Astellas and Pfizer.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Imbruvica, co-developed by AbbVie and Johnson & Johnson.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Biogen's Tysabri and Spinraza.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Gilead's Trodelvy.
More positive than 30% of relationship scores this week
[mutual] Royalty Pharma holds royalties on Vertex's Trikafta and Alyftrek.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
11h ago
+30.0%
Price agrees with the score
$60.27 vs $46.35 close before publication (Mar 27) · not market-adjusted
RPRX chart →
